Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01803438
Recruitment Status : Recruiting
First Posted : March 4, 2013
Last Update Posted : February 6, 2018
Information provided by (Responsible Party):
Medtronic Atrial Fibrillation Solutions

Brief Summary:
The purpose of this study is to evaluate the effectiveness of Pulmonary Vein Isolation (PVI) performed with the Arctic Front™ Advance Cardiac CryoAblation Catheter System as first-line therapy in comparison with antiarrhythmic drugs (AAD) in patients with paroxysmal atrial fibrillation (AF).

Condition or disease Intervention/treatment Phase
Symptomatic Paroxysmal Atrial Fibrillation Without Clinically Significant Heart Diseases Device: cryoballoon ablation system Drug: Antiarrhythmic Drugs Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 218 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation.
Study Start Date : June 2014
Estimated Primary Completion Date : November 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: AADs
AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
Drug: Antiarrhythmic Drugs
AAD therapy based on hospital clinical practice according to ESC Guidelines 2012

Experimental: Cryoablation procedure
electrical pulmonary veins isolation performed with cryoballoon ablation system
Device: cryoballoon ablation system

Primary Outcome Measures :
  1. Freedom from any atrial arrhythmia recurrence [ Time Frame: 12 months ]
    The primary endpoint is freedom from any atrial arrhythmia recurrence at 12 months (at least one episode of AF, atrial flutter or atrial tachycardia with a duration > 30 seconds documented by 7 day Holter ECG or any other printed ECG recording following a blanking period or a dosing optimizing period of 3 months).

Secondary Outcome Measures :
  1. quality of life [ Time Frame: 12 months ]
    The quality of life of the two arms measured by means of SF-36 Health Survey and Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaires will be compared at 12 months follow-up.

  2. Hospital or emergency services accesses [ Time Frame: 12 Months ]
    Hospital or emergency services accesses due to symptoms caused by documented atrial arrhythmias will be compared in the two arms at 12 months follow-up.

  3. Freedom from occurrence of AF [ Time Frame: 12 months ]
    Freedom from occurrence of AF (after 3 months blanking period) will be compared between the two arms at 12 months follow-up.

  4. Freedom from occurrence of documented left atrial tachycardia and left atrial flutter [ Time Frame: 12 months ]
    Freedom from occurrence of documented left atrial tachycardia and typical - or atypical left atrial flutter (after 3 months blanking period or AAD optimization period) will be compared between the two arms at 12 months follow-up.

  5. Symptomatic palpitations burden [ Time Frame: 12 months ]
    Symptomatic palpitations burden will be evaluated by mean of Patient's diary information and compared between the two arms at 12 months follow-up.

  6. Severe adverse events incidence [ Time Frame: 12 months ]
    Severe adverse events incidence will be compared between the two arms during the whole course of the study.

  7. Freedom from persistent AF [ Time Frame: 12 months ]
    Freedom from persistent AF (AF episode lasting longer than 7 days or interrupted by pharmacological or electrical cardioversion after 48h from the onset of the episode) will be compared between the two arms at 12 months follow-up.

  8. Echocardiographic left atrial re-modelling [ Time Frame: 12 months ]
    Echocardiographic left atrial parameters will be compared between the two arms at 6 and 12 months follow ups.

  9. health care utilization [ Time Frame: 12 months ]
    Frequency, type and associated cost of health care utilization and utility will be compared between the two arms at 12 months follow-up.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has been diagnosed with symptomatic paroxysmal atrial fibrillation as defined above and at least two symptomatic episodes in the last six months prior to inclusion.
  • At least one episode of AF must be documented during the prior year by any kind of ECG recording.
  • Subject has structural normal heart with an LVEF ≥ 50%, thickness of the inter-ventricular septum ≤12 mm and left atrium diameters (short axis) < 46 mm obtained by transthoracic echocardiography.
  • Subject has normal ECG parameters (QRS width in the 12 channel surface ECG ≤120 ms, QTc - interval < 440 ms, PQ - interval ≤ 210 ms; all parameters should be measured at sinus rhythm).
  • Subject is at least 18 and not older than 75years old.
  • Subject is able and willing to give informed consent.

Exclusion Criteria:

  • Subject developed persistent AF at least once in history (electrical or pharmacological cardioversion after 48h or episode duration >7 days).

    • Subject has documented typical atrial flutter.
    • Subject has any history of successful or unsuccessful treatment of AF with class I or III antiarrhythmic or sotalol with the intention to prevent an AF recurrence. Patients pretreated with above AAD at maximum 48 hours with the intention to convert an AF episode are allowed.
    • Subject had any previous left atrial ablation.
    • Subject had any previous cardiac surgery, e.g. prosthetic valves.
    • Subject has permanent pacemaker or defibrillator implant.
    • Subject has 2° type II, 3° degree AV-block or left/right bundle branch block pattern.
    • Subject has unstable angina pectoris.
    • Subject has history of previous myocardial infarction or percutaneous intervention during the last three months.
    • Subject has symptomatic carotid stenosis.
    • Subject has chronic obstructive pulmonary disease with detected pulmonary hypertension or any other evidence of significant lung disease.
    • Subject has any contraindication for oral anticoagulation.
    • Subject has any history of previous transient ischemic attack or stroke.
    • Subject has known intra-cardiac thrombus formation.
    • Subject has any significant congenital heart defect corrected or not (except for patent foramen ovale that is allowed).
    • Subject has evidence of congestive heart failure (NYHA class II, III or IV) in sinus rhythm.
    • Subject has hypertrophic cardiomyopathy.
    • Subject has abnormal long or short QT interval, signs of Brugada syndrome, known inheriting ion channel disease on the family, arrhythmogenic right ventricular dysplasia.
    • Subject has sarcoidosis.
    • Subject has pulmonary vein stent.
    • Subject has myxoma. Exclusion criteria based on laboratory abnormalities
    • Subject has thrombocytosis (platelet count > 600,000 / μl) or thrombocytopenia (platelet count <100,000 / μl).
    • Subject has any untreated or uncontrolled hyperthyroidism or hypothyroidism.
    • Subject has renal dysfunction with glomerular filtration rate < 60 ml / min.
    • Subject has known cryoglobulinaemia. General exclusion criteria
    • Subject has a reversible causes for AF like hyperthyroidism and alcoholism.
    • Subject is a pregnant woman or woman of childbearing potential not on adequate birth control: only woman with a highly effective method of contraception [oral contraception or intra-uterine device] (who must have a negative pregnancy test within 1 week of the start of the therapy) or sterile woman can be enrolled.
    • Subject is a breastfeeding woman.
    • Subject has an active systemic infection.
    • Subject is employed by Medtronic or by the department of any of the investigators or is a close relative of any of the investigators.
    • Subject is unwilling or unable to comply fully with study procedures and follow-up due to any disease condition, which can raise doubt about compliance and influencing the study outcome especially any kind of cancer, severe bleeding in history or a suspected pro-coagulant state.
    • Legal incapacity or evidence that a subject cannot understand the purpose and risks of the study or inability to comply fully with study procedures and follow up.
    • Subject has a life expectancy of ≤ 1 year.
    • Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01803438

Contact: Laura Manotta, MS +39 02 241371 laura.manotta@|

Monash Medical Centre Recruiting
Melbourne, Australia
Contact: Stewart Healy, Dr         
Heart Rhythm Management Centre, UZ Brussels - VUB Brussel Recruiting
Brussel, Belgium
Klinicki bolnicki centar Sestre Milosrdnice Recruiting
Zagreb, Croatia
Contact: Pavlovic, Dr.         
Klinicki bolnicki centar Sestre Recruiting
Zagreb, Croatia
Contact: Velagic, Dr         
NCHU Amiens Recruiting
Amiens, France
Contact: Hermida, Prof         
CHU Grenoble Recruiting
Grenoble, France
Contact: Defaye, Dr         
CHU La Pitié Recruiting
Paris, France
Contact: Badenco, Dr         
CHU Charles Nicolle Recruiting
Rouen, France
Contact: Anselme, Prof         
Kerckhoff - Klinik Recruiting
Bad Nauheim, Germany
Cardioangiologisches Centrum Bethanien Recruiting
Frankfurt, Germany, 60431
Contact: Julian Chun, PD         
Universitätsklinikum Eppendorf Recruiting
Hamburg, Germany, 20246
Westpfalz-Klinikum GmbH Recruiting
Kaiserslautern, Germany, 67655
Klinikum Bogenhausen Terminated
Munich, Germany
Maria Cecilia Hospital Recruiting
Cotignola, Italy, 48033
Ospedale S.S. Giacomo e Cristoforo Recruiting
Massa, Italy
Contact: Arena , Dr         
Haukeland Hospital Recruiting
Bergen, Norway
Contact: Chen, Dr         
Sponsors and Collaborators
Medtronic Atrial Fibrillation Solutions
Principal Investigator: Malte Kuniss, MD Kerckhoff - Klinik, Bad Nauheim, Germany
Principal Investigator: GianBattista Chierchia, MD Heart Rhythm Management Centre, UZ Brussels - VUB Brussel, Belgium

Responsible Party: Medtronic Atrial Fibrillation Solutions Identifier: NCT01803438     History of Changes
Other Study ID Numbers: Cryo-FIRST
First Posted: March 4, 2013    Key Record Dates
Last Update Posted: February 6, 2018
Last Verified: February 2018

Keywords provided by Medtronic Atrial Fibrillation Solutions:
paroxysmal Atrial Fibrillation
Pulmonary Vein Isolation

Additional relevant MeSH terms:
Atrial Fibrillation
Heart Diseases
Arrhythmias, Cardiac
Cardiovascular Diseases
Pathologic Processes
Anti-Arrhythmia Agents